Physician profile
Christopher J Waguespack
NPI 1275775165
$1,960.96
in general payments reported to CMS, 2019-2025
34 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $85.43 · 2021: $105 · 2022: $326 · 2023: $398 · 2024: $285 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.76 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $292.53 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $241.04 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $174.43 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $172.55 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $152.06 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $102.69 | 2019-2023 | |
| Abbvie INC. | $93.65 | 2021-2023 | Vraylar |
| Neurocrine Biosciences, INC. | $85.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.66 | 2019-2025 | Jardiance |
| Amgen INC. | $53.95 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $48.40 | 2019-2022 | |
| Antares Pharma, INC. | $41.12 | 2021-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $36.32 | 2019 | |
| Sumitomo Pharma America, INC. | $31.85 | 2025 | Gemtesa |
| Genentech USA, INC. | $30.89 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.15 | 2019-2022 | |
| Ibsa Pharma INC. | $22.78 | 2020 | |
| Shire North American Group INC | $20.91 | 2019 | |
| Amarin Pharma, INC. | $20.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Almatica Pharma LLC | $17.46 | 2023 | Loreev Xr |
| Tris Pharma INC | $16.75 | 2025 | Dyanavel Xr |
| Aytu Biopharma, INC. | $16.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.10 | 2019 | |
| Intra-Sana Laboratories | $15.96 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Halozyme INC | $15.16 | 2023 | |
| Endo Pharmaceuticals INC. | $14.76 | 2019 | |
| Corcept Therapeutics | $14.33 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $12.20 | 2022 | |
| Eisai INC. | $11.88 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.72 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.34 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Waguespack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.